Knights of Columbus Asset Advisors LLC Sells 6,598 Shares of Stryker Corporation $SYK

Key Points

• Knights of Columbus Asset Advisors cut its Stryker stake by 27.3% in the fourth quarter, selling 6,598 shares and ending with 17,612 shares valued at about $6.19 million.
• Insider selling also continued, with VP M Kathryn Fink selling 5,220 shares on May 11 for roughly $1.48 million, reducing her holdings by 28.44%.
• Stryker’s latest results came in below expectations, with Q1 EPS of $2.60 versus $2.98 expected and revenue of $6.02 billion versus $6.34 billion expected, even as the company maintained FY 2026 EPS guidance of 14.90 to 15.10.

Knights of Columbus Asset Advisors LLC decreased its position in shares of Stryker Corporation (NYSE:SYK - Free Report) by 27.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 17,612 shares of the medical technology company's stock after selling 6,598 shares during the quarter. Knights of Columbus Asset Advisors LLC's holdings in Stryker were worth $6,190,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. lifted its position in Stryker by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company's stock worth $11,917,396,000 after purchasing an additional 133,892 shares during the period. Alliancebernstein L.P. raised its stake in Stryker by 13.3% during the third quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company's stock worth $2,342,987,000 after acquiring an additional 741,542 shares in the last quarter. Legal & General Group Plc raised its stake in Stryker by 2.7% during the fourth quarter. Legal & General Group Plc now owns 2,366,107 shares of the medical technology company's stock worth $831,616,000 after acquiring an additional 62,817 shares in the last quarter. Corient Private Wealth LLC raised its stake in Stryker by 104.4% during the second quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company's stock worth $887,525,000 after acquiring an additional 1,146,998 shares in the last quarter. Finally, Invesco Ltd. raised its stake in Stryker by 4.5% during the third quarter. Invesco Ltd. now owns 1,864,918 shares of the medical technology company's stock worth $689,404,000 after acquiring an additional 80,536 shares in the last quarter. Institutional investors own 77.09% of the company's stock.

Insider Activity

In other news, VP M Kathryn Fink sold 5,220 shares of the company's stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $283.85, for a total value of $1,481,697.00. Following the completion of the transaction, the vice president owned 13,137 shares of the company's stock, valued at $3,728,937.45. This represents a 28.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 4.60% of the stock is owned by corporate insiders.

Stryker Stock Performance

Stryker stock opened at $306.16 on Thursday. The business has a 50 day moving average of $323.45 and a 200-day moving average of $348.79. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $404.87. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. The company has a market capitalization of $117.37 billion, a P/E ratio of 35.44, a P/E/G ratio of 1.97 and a beta of 0.80.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The firm had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. During the same period in the prior year, the company earned $2.84 EPS. The business's quarterly revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, equities research analysts predict that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. Stryker's dividend payout ratio is currently 40.74%.

Analyst Upgrades and Downgrades

SYK has been the subject of several research analyst reports. Jefferies Financial Group reissued a "buy" rating and set a $465.00 target price on shares of Stryker in a research note on Wednesday, March 4th. UBS Group lowered their target price on Stryker from $400.00 to $380.00 and set a "neutral" rating for the company in a research note on Tuesday, March 17th. William Blair reissued an "outperform" rating on shares of Stryker in a research note on Thursday, March 5th. JPMorgan Chase & Co. lowered their target price on Stryker from $445.00 to $400.00 and set an "overweight" rating for the company in a research note on Friday, May 1st. Finally, Citigroup lowered their target price on Stryker from $420.00 to $385.00 and set a "buy" rating for the company in a research note on Tuesday, April 7th. Sixteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $395.48.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.